

Reference number(s) 2166-A

Jurisdiction Specific Medicare Part B Xeomin

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Xeomin	incobotulinumtoxin A

Covered Uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Cervical dystonia in adults
- Blepharospasm in adults
- Upper limb spasticity
- · Chronic sialorrhea in patients 2 years of age and older

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

Exclusions

Coverage will not be provided for cosmetic use.

Coverage Criteria

Chronic Sialorrhea

Xeomin MedB Jurisdiction N (FL PR USVI) 2166-A P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)	
2166-A	

Authorization of 12 months may be granted for the treatment of chronic sialorrhea in members 2 years of age and older.

Upper Limb Spasticity In Adults

Authorization of 12 months may be granted for the treatment of upper limb spasticity in adults.

Upper Limb Spasticity in Pediatric Members

Authorization of 12 months may be granted for the treatment of upper limb spasticity in pediatric members 2 to 17 years of age, excluding spasticity caused by cerebral palsy.

Cervical Dystonia

Authorization of 12 months may be granted for the treatment of adults with cervical dystonia.

Blepharospasm

Authorization of 12 months may be granted for the treatment of blepharospasm in adults.

Dosage and Administration

The lowest effective dose and longest dosing interval that produces the desired clinical effect should be used.

References

- 1. Botulinum Toxins LCD (L33274) Version R11. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed July 23, 2024.
- 2. Billing and Coding: Botulinum Toxins (A57715) Version R10. Available at: Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed July 23, 2024.
- 3. Xeomin [package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; July 2024.

Xeomin MedB Jurisdiction N (FL PR USVI) 2166-A P2024.docx

© 2024 CVS Caremark. All rights reserved.